Valuation: NetraMark Holdings Inc.

Market Cap 65.85M 46.66M 41.02M 38.19M 35.07M 4.47B 66.72M 454M 177M 2.21B 175M 171M 7.64B P/E 2026 *
-
P/E 2027 * -
Enterprise Value 65.85M 46.66M 41.02M 38.19M 35.07M 4.47B 66.72M 454M 177M 2.21B 175M 171M 7.64B EV / Sales 2026 *
164x
EV / Sales 2027 * -
Free-Float
91.14%
Yield 2026 *
-
Yield 2027 * -
Jul. 09 NetraMark Up 11% as It Signs a New Contract To Analyze Phase 2 Neurodegeneration Trial Data MT
Jul. 09 NetraMark Holdings Inc. Signs Contract To Analyze Phase 2 Neurodegeneration Trial Data With Contract Research Organization Partner CI
Jun. 29 NetraMark to Perform AI-Assisted Analysis of Clinical Trial Data For Biopharm Company MT
Jun. 29 NetraMark Holdings Inc. Signs NetraAI Clinical Trial Analysis Agreement with Late-Stage Biopharmaceutical Company CI
May. 14 NetraMark Holdings Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2026 CI
May. 07 NetraMark Holdings Inc. Announces Resignation of Lawrence Guy as Director, Effective May 7, 2026 CI
May. 04 NetraMark Holdings Inc. Announces Executive Changes CI
Apr. 22 NetraMark Holdings Inc. Positioned to Advance Psychedelic Clinical Trials Following U.S. Executive Order, Supported by Peer-Reviewed Research and Active Programs CI
Apr. 20 NetraMark Holdings Inc Announces NetraAI Platform For Clinical Trial Precision Analytics CI
Apr. 09 Netramark Holdings Inc Announces Publication of Peer-Reviewed Article on Psychedelics and Quantum Brain Processes CI
Mar. 25 NetraMark Collaborating With Italian Company To Analyze Phase II Oncology Dataset MT
Mar. 25 Netramark Holdings Inc. and Fondazione Per La Medicina Personalizzata Announce Strategic Research Collaboration CI
Mar. 25 NetraMark Brief: Announcing Strategic Oncology Research Collaboration with Fondazione per la Medicina Personalizzata to Analyze Landmark ROME Trial Dataset MT
1 day-6.76%
Current month+32.47%
1 month+26.45%
3 months-13.70%
6 months-38.10%
Current year-33.15%
1 month 0.4
Extreme 0.4013
0.66
Current year 0.4
Extreme 0.4013
0.89
1 year 0.4
Extreme 0.4013
1.26
3 years 0.11
Extreme 0.114
1.26
5 years 0.1
Extreme 0.1045
1.61
10 years 0.1
Extreme 0.1045
1.61
Manager TitleAgeSince
Chief Executive Officer - 2022-02-16
President - 2022-07-03
Director of Finance/CFO 57 2022-07-17
Director TitleAgeSince
Chairman 40 2025-06-08
Director/Board Member - -
Director/Board Member - 2022-06-15
Change 5-day change 1-year change 3-year change Capi.($)
-6.76%0.00% - - 51.37M
+1.94%-3.28%-24.26%+17.65% 2,835B
+7.00%-2.46%-17.17%+714.43% 295B
+1.31%+4.24%+174.64%+991.44% 114B
+3.79%+2.63%+1.93%+44.15% 89.98B
+2.03%-4.31%+68.09%+130.09% 87.87B
+4.16%+2.78%-35.34%-13.32% 71.51B
+4.39%-1.23%-33.81%+73.26% 61.25B
+5.31%+2.08%+8.54%+62.80% 43.01B
+1.83%-9.07%-59.25%+27.72% 34.04B
Average +1.05%-4.24%+9.26%+227.58% 403.49B
Weighted average by Cap. -0.38%-3.55%-14.89%+109.01%

Financials

2026 *2027 *
Net sales 401K 284K 250K 232K 214K 27.25M 406K 2.76M 1.08M 13.45M 1.07M 1.04M 46.5M -
Net income - -
Net Debt - -
Logo NetraMark Holdings Inc.
NetraMark Holdings Inc. is a Canada-based company, which is focused on the development of Generative Artificial Intelligence (Gen AI)/Machine Learning (ML) solutions targeted at the pharmaceutical industry. The Company’s product offering uses a novel topology-based algorithm that has the ability to parse patient data sets into subsets of people that are strongly related according to several variables simultaneously. This allows the Company to use a variety of ML methods, depending on the character and size of the data, to transform the data into powerfully intelligent data that activates traditional AI/ML methods. The result is that it can work with smaller datasets and accurately segment diseases into different types, as well as accurately classify patients for sensitivity to drugs and/or efficacy of treatment. The typical molecular data used is RNASeq, microarray, single nucleotide polymorphism (SNP) and methylation.
Employees
-
Date Price Change Volume

Quarterly revenue - Rate of surprise